A detailed history of Godsey & Gibb Associates transactions in Novartis Ag stock. As of the latest transaction made, Godsey & Gibb Associates holds 191,338 shares of NVS stock, worth $18.8 Million. This represents 2.11% of its overall portfolio holdings.

Number of Shares
191,338
Previous 190,918 0.22%
Holding current value
$18.8 Million
Previous $20.3 Million 8.28%
% of portfolio
2.11%
Previous 2.1%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$106.13 - $120.89 $44,574 - $50,773
420 Added 0.22%
191,338 $22 Million
Q2 2024

Jul 23, 2024

SELL
$92.57 - $107.37 $587,541 - $681,477
-6,347 Reduced 3.22%
190,918 $20.3 Million
Q1 2024

Apr 23, 2024

BUY
$95.27 - $108.47 $155,194 - $176,697
1,629 Added 0.83%
197,265 $19.1 Million
Q4 2023

Jan 16, 2024

BUY
$92.27 - $101.54 $143,295 - $157,691
1,553 Added 0.8%
195,636 $19.8 Million
Q3 2023

Oct 25, 2023

SELL
$94.73 - $105.13 $290,915 - $322,854
-3,071 Reduced 1.56%
194,083 $19.8 Million
Q2 2023

Jul 25, 2023

SELL
$92.52 - $104.91 $601,750 - $682,334
-6,504 Reduced 3.19%
197,154 $19.9 Million
Q1 2023

Apr 18, 2023

BUY
$80.03 - $92.81 $16.3 Million - $18.9 Million
203,658 New
203,658 $18.7 Million
Q1 2022

Apr 28, 2022

SELL
$80.11 - $90.62 $15.3 Million - $17.3 Million
-191,150 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$79.7 - $88.13 $498,125 - $550,812
6,250 Added 3.38%
191,150 $16.7 Million
Q3 2021

Nov 12, 2021

BUY
$81.78 - $95.14 $15.1 Million - $17.6 Million
184,900 New
184,900 $15.1 Million
Q2 2021

Aug 05, 2021

SELL
$85.24 - $94.15 $15 Million - $16.6 Million
-176,123 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$83.5 - $98.47 $414,661 - $489,002
4,966 Added 2.9%
176,123 $15.1 Million
Q4 2020

Feb 12, 2021

BUY
$78.07 - $94.43 $414,161 - $500,951
5,305 Added 3.2%
171,157 $16.2 Million
Q3 2020

Nov 10, 2020

BUY
$82.14 - $91.0 $69,572 - $77,077
847 Added 0.51%
165,852 $14.4 Million
Q2 2020

Aug 12, 2020

SELL
$80.93 - $91.1 $97,277 - $109,502
-1,202 Reduced 0.72%
165,005 $14.4 Million
Q1 2020

May 11, 2020

SELL
$70.67 - $99.01 $103,460 - $144,950
-1,464 Reduced 0.87%
166,207 $13.7 Million
Q4 2019

Feb 06, 2020

BUY
$84.35 - $95.37 $299,020 - $338,086
3,545 Added 2.16%
167,671 $15.9 Million
Q3 2019

Nov 13, 2019

BUY
$85.54 - $94.26 $167,401 - $184,466
1,957 Added 1.21%
164,126 $14.3 Million
Q2 2019

Aug 07, 2019

BUY
$75.4 - $92.8 $533,605 - $656,745
7,077 Added 4.56%
162,169 $14.8 Million
Q1 2019

May 14, 2019

BUY
$75.32 - $86.15 $498,994 - $570,743
6,625 Added 4.46%
155,092 $14.9 Million
Q4 2018

Feb 13, 2019

BUY
$73.66 - $82.02 $302,816 - $337,184
4,111 Added 2.85%
148,467 $12.7 Million
Q3 2018

Nov 13, 2018

BUY
$66.94 - $77.43 $810,710 - $937,754
12,111 Added 9.16%
144,356 $12.4 Million
Q2 2018

Aug 14, 2018

SELL
$64.91 - $73.36 $920,748 - $1.04 Million
-14,185 Reduced 9.69%
132,245 $9.99 Million
Q1 2018

May 11, 2018

BUY
$70.39 - $84.15 $292,822 - $350,064
4,160 Added 2.92%
146,430 $11.8 Million
Q4 2017

Jan 23, 2018

SELL
$72.33 - $77.64 $71,100 - $76,320
-983 Reduced 0.69%
142,270 $11.9 Million
Q3 2017

Nov 03, 2017

SELL
$74.14 - $77.27 $547,746 - $570,870
-7,388 Reduced 4.9%
143,253 $12.3 Million
Q2 2017

Aug 11, 2017

BUY
N/A
150,641
150,641 $12.6 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $212B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Godsey & Gibb Associates Portfolio

Follow Godsey & Gibb Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Godsey & Gibb Associates, based on Form 13F filings with the SEC.

News

Stay updated on Godsey & Gibb Associates with notifications on news.